http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I646961-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b6030795999b0ece55a2735b5413921 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2016-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5abd38c84e1b219e29f6dbfb09f50780 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ca704cc20eaf6eb35c0b0ffb5600144 |
| publicationDate | 2019-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-I646961-B |
| titleOfInvention | Dehydrothiamine [2,3- c Use of a quinoline-12-one derivative for the preparation of a medicament for treating non-small cell lung cancer |
| abstract | One kind dehydrogenation thiamine [2,3- c] quinolin-12-one derivative (thiochromeno [2,3- c] quinolin- 12-one derivatives) of a medicament for treating non small cell lung cancer, the stripper The thiamine [2,3- c ]quinolin-12-one derivative acts similarly to the HSP90 inhibitor, overcoming EGFR-TKI resistance and poisoning EGFR-mutant NSCLC cells by simultaneously degrading EGFR and cMET proteins, but N19 is not Like HSP90 inhibitors, there is no cytotoxicity to retinal cells. |
| priorityDate | 2016-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.